Listed

CG Oncology, Inc.

CGONNasdaqCIK 1991792HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.2m, Q2 FY2026
Operating income−$86.4m, Q2 FY2026
Net income−$79.1m, Q2 FY2026
CG Oncology, Inc., income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, period not labelled, three months to 2023-09-30$9.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure0.0Revenue, period not labelled, three months to 2023-12-31$1.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure0.5Revenue, Q1 FY2024, three months to 2024-03-31$529.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure0.1Revenue, Q2 FY2024, three months to 2024-06-30$111.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$43.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure0.5Revenue, Q4 FY2024, three months to 2024-12-31$456.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$52.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure1.7Revenue, Q3 FY2025, three months to 2025-09-30$1.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure2.3Revenue, Q4 FY2025, three months to 2025-12-31$2.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure1.1Revenue, Q1 FY2026, three months to 2026-03-31$1.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure1.2Revenue, Q2 FY2026, three months to 2026-06-30$1.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Research and development$m11.7Research and development, period not labelled, three months to 2023-09-30$11.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure16.3Research and development, period not labelled, three months to 2023-12-31$16.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure17.2Research and development, Q1 FY2024, three months to 2024-03-31$17.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure18.5Research and development, Q2 FY2024, three months to 2024-06-30$18.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure19.6Research and development, Q3 FY2024, three months to 2024-09-30$19.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure26.8Research and development, Q4 FY2024, three months to 2024-12-31$26.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure27.5Research and development, Q1 FY2025, three months to 2025-03-31$27.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure31.3Research and development, Q2 FY2025, three months to 2025-06-30$31.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure27.9Research and development, Q3 FY2025, three months to 2025-09-30$27.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure30.0Research and development, Q4 FY2025, three months to 2025-12-31$30.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure43.7Research and development, Q1 FY2026, three months to 2026-03-31$43.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure54.7Research and development, Q2 FY2026, three months to 2026-06-30$54.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Operating income$m(14.0)Operating income, period not labelled, three months to 2023-09-30−$14.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure(19.4)Operating income, period not labelled, three months to 2023-12-31−$19.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(22.5)Operating income, Q1 FY2024, three months to 2024-03-31−$22.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure(25.9)Operating income, Q2 FY2024, three months to 2024-06-30−$25.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure(28.3)Operating income, Q3 FY2024, three months to 2024-09-30−$28.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(38.0)Operating income, Q4 FY2024, three months to 2024-12-31−$38.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(42.2)Operating income, Q1 FY2025, three months to 2025-03-31−$42.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(48.7)Operating income, Q2 FY2025, three months to 2025-06-30−$48.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(51.1)Operating income, Q3 FY2025, three months to 2025-09-30−$51.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(48.7)Operating income, Q4 FY2025, three months to 2025-12-31−$48.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(66.4)Operating income, Q1 FY2026, three months to 2026-03-31−$66.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(86.4)Operating income, Q2 FY2026, three months to 2026-06-30−$86.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Net income$m(11.8)Net income, period not labelled, three months to 2023-09-30−$11.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure(16.6)Net income, period not labelled, three months to 2023-12-31−$16.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(16.9)Net income, Q1 FY2024, three months to 2024-03-31−$16.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(18.9)Net income, Q2 FY2024, three months to 2024-06-30−$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(20.4)Net income, Q3 FY2024, three months to 2024-09-30−$20.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(31.8)Net income, Q4 FY2024, three months to 2024-12-31−$31.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(34.5)Net income, Q1 FY2025, three months to 2025-03-31−$34.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(41.4)Net income, Q2 FY2025, three months to 2025-06-30−$41.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(43.8)Net income, Q3 FY2025, three months to 2025-09-30−$43.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure(41.3)Net income, Q4 FY2025, three months to 2025-12-31−$41.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(60.2)Net income, Q1 FY2026, three months to 2026-03-31−$60.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(79.1)Net income, Q2 FY2026, three months to 2026-06-30−$79.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Diluted EPS$ per share(4.00)Diluted EPS, period not labelled, three months to 2023-09-30−$4.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figurenot reported(0.36)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure(0.28)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure(0.30)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figurenot reported(0.45)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(0.54)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(0.57)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figurenot reported(0.71)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(0.90)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Basic EPS$ per share(4.00)Basic EPS, period not labelled, three months to 2023-09-30−$4.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figurenot reported(0.36)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure(0.28)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure(0.30)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.30 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figurenot reported(0.45)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(0.54)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.54 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure(0.57)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figurenot reported(0.71)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(0.90)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.90 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure

Balance sheet

Cash and equivalents$19.6m, Q2 FY2026
Long-term debt$3.0m, Q2 FY2026
Shareholders' equity$1.03bn, Q2 FY2026
CG Oncology, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reported8.3Cash and equivalents, period not labelled, at 2023-12-31$8.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-28, accession 0000950170-25-046351.Report this figure77.5Cash and equivalents, Q1 FY2024, at 2024-03-31$77.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure25.2Cash and equivalents, Q2 FY2024, at 2024-06-30$25.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure43.4Cash and equivalents, Q3 FY2024, at 2024-09-30$43.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure257Cash and equivalents, FY2024, at 2024-12-31$257.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure41.5Cash and equivalents, Q1 FY2025, at 2025-03-31$41.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure14.6Cash and equivalents, Q2 FY2025, at 2025-06-30$14.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure45.1Cash and equivalents, Q3 FY2025, at 2025-09-30$45.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure32.5Cash and equivalents, FY2025, at 2025-12-31$32.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure33.7Cash and equivalents, Q1 FY2026, at 2026-03-31$33.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure19.6Cash and equivalents, Q2 FY2026, at 2026-06-30$19.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Current assets$mnot reported194Current assets, period not labelled, at 2023-12-31$194.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-28, accession 0000950170-25-046351.Report this figure579Current assets, Q1 FY2024, at 2024-03-31$578.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure564Current assets, Q2 FY2024, at 2024-06-30$563.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure552Current assets, Q3 FY2024, at 2024-09-30$552.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure754Current assets, FY2024, at 2024-12-31$754.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure701Current assets, Q1 FY2025, at 2025-03-31$701.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure673Current assets, Q2 FY2025, at 2025-06-30$673.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure696Current assets, Q3 FY2025, at 2025-09-30$695.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure759Current assets, FY2025, at 2025-12-31$759.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure1,102Current assets, Q1 FY2026, at 2026-03-31$1.10bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure1,050Current assets, Q2 FY2026, at 2026-06-30$1.05bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Total assets$mnot reported199Total assets, period not labelled, at 2023-12-31$199.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-28, accession 0000950170-25-046351.Report this figure579Total assets, Q1 FY2024, at 2024-03-31$579.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure564Total assets, Q2 FY2024, at 2024-06-30$564.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure552Total assets, Q3 FY2024, at 2024-09-30$552.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure755Total assets, FY2024, at 2024-12-31$754.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure728Total assets, Q1 FY2025, at 2025-03-31$728.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure701Total assets, Q2 FY2025, at 2025-06-30$701.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure730Total assets, Q3 FY2025, at 2025-09-30$729.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure792Total assets, FY2025, at 2025-12-31$791.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure1,135Total assets, Q1 FY2026, at 2026-03-31$1.14bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure1,086Total assets, Q2 FY2026, at 2026-06-30$1.09bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Current liabilities$mnot reported14.3Current liabilities, period not labelled, at 2023-12-31$14.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-28, accession 0000950170-25-046351.Report this figure10.0Current liabilities, Q1 FY2024, at 2024-03-31$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure11.9Current liabilities, Q2 FY2024, at 2024-06-30$11.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure15.6Current liabilities, Q3 FY2024, at 2024-09-30$15.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure21.4Current liabilities, FY2024, at 2024-12-31$21.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure22.6Current liabilities, Q1 FY2025, at 2025-03-31$22.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure30.4Current liabilities, Q2 FY2025, at 2025-06-30$30.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure30.5Current liabilities, Q3 FY2025, at 2025-09-30$30.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure30.8Current liabilities, FY2025, at 2025-12-31$30.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure35.2Current liabilities, Q1 FY2026, at 2026-03-31$35.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure47.2Current liabilities, Q2 FY2026, at 2026-06-30$47.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Total liabilities$mnot reported14.5Total liabilities, period not labelled, at 2023-12-31$14.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-28, accession 0000950170-25-046351.Report this figure10.2Total liabilities, Q1 FY2024, at 2024-03-31$10.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure12.0Total liabilities, Q2 FY2024, at 2024-06-30$12.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure15.7Total liabilities, Q3 FY2024, at 2024-09-30$15.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure21.4Total liabilities, FY2024, at 2024-12-31$21.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure23.4Total liabilities, Q1 FY2025, at 2025-03-31$23.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure31.1Total liabilities, Q2 FY2025, at 2025-06-30$31.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure42.3Total liabilities, Q3 FY2025, at 2025-09-30$42.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure39.0Total liabilities, FY2025, at 2025-12-31$39.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure43.5Total liabilities, Q1 FY2026, at 2026-03-31$43.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure56.5Total liabilities, Q2 FY2026, at 2026-06-30$56.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reported0.0Long-term debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figurenot reportednot reported3.0Long-term debt, Q3 FY2025, at 2025-09-30$3.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure3.0Long-term debt, FY2025, at 2025-12-31$3.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure3.0Long-term debt, Q1 FY2026, at 2026-03-31$3.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure3.0Long-term debt, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure
Shareholders' equity$m(108)Shareholders' equity, period not labelled, at 2023-09-30−$107.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure(123)Shareholders' equity, period not labelled, at 2023-12-31−$123.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-27, accession 0001193125-26-079498.Report this figure569Shareholders' equity, Q1 FY2024, at 2024-03-31$568.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure552Shareholders' equity, Q2 FY2024, at 2024-06-30$552.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure537Shareholders' equity, Q3 FY2024, at 2024-09-30$536.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure733Shareholders' equity, FY2024, at 2024-12-31$733.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure705Shareholders' equity, Q1 FY2025, at 2025-03-31$704.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure670Shareholders' equity, Q2 FY2025, at 2025-06-30$670.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure688Shareholders' equity, Q3 FY2025, at 2025-09-30$687.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure753Shareholders' equity, FY2025, at 2025-12-31$752.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure1,092Shareholders' equity, Q1 FY2026, at 2026-03-31$1.09bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure1,029Shareholders' equity, Q2 FY2026, at 2026-06-30$1.03bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure

Cash flow

Operating cash flow−$46.4m, Q2 FY2026
Capital expenditure$468.0k, Q2 FY2026
CG Oncology, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(12.3)Operating cash flow, period not labelled, three months to 2023-09-30−$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0000950170-24-124642. Derived: 9-month figure less the 6-month figure.Report this figure(14.6)Operating cash flow, period not labelled, three months to 2023-12-31−$14.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(26.0)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$26.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure(16.1)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$16.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-08, accession 0000950170-25-105855. Derived: 6-month figure less the 3-month figure.Report this figure(15.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$15.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001193125-25-283000. Derived: 9-month figure less the 6-month figure.Report this figure(20.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$20.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(29.3)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$29.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(28.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$28.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336918. Derived: 6-month figure less the 3-month figure.Report this figure(38.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$38.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001193125-25-283000. Derived: 9-month figure less the 6-month figure.Report this figure(36.2)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$36.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure(56.9)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$56.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure(46.4)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$46.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336918. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reported0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$12.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-08, accession 0000950170-25-105855. Derived: 6-month figure less the 3-month figure.Report this figure(0.0)Capital expenditure, Q3 FY2024, three months to 2024-09-30−$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-283000. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$209.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336918. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$97.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-14, accession 0001193125-25-283000. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-27, accession 0001193125-26-079498. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2026, three months to 2026-03-31$304.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure0.5Capital expenditure, Q2 FY2026, three months to 2026-06-30$468.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336918. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)88.20m, Q2 FY2026
CG Oncology, Inc., shares, quarterly
Line itemUnitperiod not labelled2023-03-31period not labelled2023-06-30period not labelled2023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares3.9Diluted shares (weighted), period not labelled, three months to 2023-03-313,855,383 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-056196.Report this figure3.9Diluted shares (weighted), period not labelled, three months to 2023-06-303,918,509 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-093238.Report this figure4.4Diluted shares (weighted), period not labelled, three months to 2023-09-304,383,131 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0000950170-24-124642.Report this figure47.1Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3147,064,768 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-069831.Report this figure66.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3066,649,443 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-08, accession 0000950170-25-105855.Report this figure67.1Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3067,143,744 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure76.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3176,187,621 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure76.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3076,226,829 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure76.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3076,729,726 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001193125-25-283000.Report this figure84.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3184,518,512 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-08, accession 0001193125-26-214669.Report this figure88.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3088,200,023 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure

Shares outstanding: 88.64mShares outstanding, period not labelled, at 2026-08-0588,640,375 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-336918.Report this figure at Aug 5, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.